InspireMD Appoints New CFO Amidst Strategic Expansion

An update from InspireMD ( (NSPR) ) is now available.

On June 3, 2025, InspireMD announced the appointment of Michael Lawless as Chief Financial Officer, effective by June 30, 2025. Lawless, who brings extensive financial leadership experience from the healthcare sector, will replace Craig Shore, who has been with the company for nearly 15 years. This leadership change comes as InspireMD prepares for the U.S. launch of its CGuard Prime system, marking a significant phase in its commercial expansion. In connection with his appointment, Lawless will receive an inducement grant of restricted stock and stock options, which will vest over three years, aligning with Nasdaq Listing Rule 5635(c)(4).

The most recent analyst rating on (NSPR) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on InspireMD stock, see the NSPR Stock Forecast page.

Spark’s Take on NSPR Stock

According to Spark, TipRanks’ AI Analyst, NSPR is a Neutral.

InspireMD’s score is driven by financial challenges and valuation concerns, despite some growth potential highlighted in the earnings call. The company’s profitability issues and negative cash flow are significant risks, while technical analysis and growth prospects provide some balance.

To see Spark’s full report on NSPR stock, click here.

More about InspireMD

InspireMD, Inc. is a company focused on developing the CGuard™ Prime carotid stent system, aimed at treating carotid artery disease and preventing strokes. The company utilizes its proprietary MicroNet® technology to set industry standards for carotid stenting, providing excellent acute results and long-term stroke-free outcomes. InspireMD is publicly traded on Nasdaq under the ticker symbol NSPR.

Average Trading Volume: 51,864

Technical Sentiment Signal: Sell

Current Market Cap: $77.81M

Learn more about NSPR stock on TipRanks’ Stock Analysis page.